Pivotal readout
Brii picks hepatitis B cure regimen for registration study after phase 2b
In the single-arm ENRICH study of 148 patients, 32.4% remained free of hepatitis B surface antigen six months after stopping BRII-179 priming followed by elebsiran and interferon. Brii chose this sequence for a potential registration trial after early talks with China's regulator. It will not fund phase 3 work with elebsiran until its arbitration with Vir is settled.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.